Simeon D Kimmel1,2,3, Alexander Y Walley1,3,4,5, Benjamin P Linas2,3, Bindu Kalesan3,6, Eric Awtry3,7, Nikola Dobrilovic3,8, Laura White9, Marc LaRochelle1,3. 1. Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA. 2. Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA. 3. Boston University School of Medicine, Boston, Massachusetts, USA. 4. Massachusetts Department of Public Health, Boston, Massachusetts, USA. 5. Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA. 6. Section of Preventative Medicine and Epidemiology, Department of Medicine Boston, Massachusetts, USA. 7. Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center Boston, Massachusetts, USA. 8. Section of Cardiac Surgery, Department of Surgery, Boston Medical Center Boston, Massachusetts, USA. 9. Department of Biostatistics, Boston University School of Public Health Boston, Massachusetts, USA.
Abstract
BACKGROUND: Injection drug use-associated infective endocarditis (IDU-IE) is rising and valve surgery is frequently indicated. The effect of initiating public outcomes reporting for aortic valve surgery on rates of valve surgery and in-hospital mortality for endocarditis is not known. METHODS: For an interrupted time series analysis, we used data from the National Inpatient Sample, a representative sample of United States inpatient hospitalizations, from January 2010 to September 2015. We included individuals aged 18-65 with an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis of endocarditis. We defined IDU-IE using a validated combination of ICD-9 codes. We used segmented logistic regression to assess for changes in valve replacement and in-hospital mortality rates after the public reporting initiation in January 2013. RESULTS: We identified 7322 hospitalizations for IDU-IE and 23 997 for non-IDU-IE in the sample, representing 36 452 national IDU-IE admissions and 119 316 non-IDU admissions, respectively. Following the implementation of public reporting in 2013, relative to baseline trends, the odds of valve replacement decreased by 4.0% per quarter (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.93-0.99), with no difference by IDU status. The odds of an in-patient death decreased by 2.0% per quarter for both IDU-IE and non-IDU-IE cases following reporting (OR 0.98, 95% CI 0.97-0.99). CONCLUSIONS: Initiating public reporting was associated with a significant decrease in valve surgery for all IE cases, regardless of IDU status, and a reduction in-hospital mortality for patients with IE. Patients with IE may have less access to surgery as a consequence of public reporting. To understand how reduced valve surgery impacts overall mortality, future studies should examine the postdischarge mortality rate.
BACKGROUND: Injection drug use-associated infective endocarditis (IDU-IE) is rising and valve surgery is frequently indicated. The effect of initiating public outcomes reporting for aortic valve surgery on rates of valve surgery and in-hospital mortality for endocarditis is not known. METHODS: For an interrupted time series analysis, we used data from the National Inpatient Sample, a representative sample of United States inpatient hospitalizations, from January 2010 to September 2015. We included individuals aged 18-65 with an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis of endocarditis. We defined IDU-IE using a validated combination of ICD-9 codes. We used segmented logistic regression to assess for changes in valve replacement and in-hospital mortality rates after the public reporting initiation in January 2013. RESULTS: We identified 7322 hospitalizations for IDU-IE and 23 997 for non-IDU-IE in the sample, representing 36 452 national IDU-IE admissions and 119 316 non-IDU admissions, respectively. Following the implementation of public reporting in 2013, relative to baseline trends, the odds of valve replacement decreased by 4.0% per quarter (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.93-0.99), with no difference by IDU status. The odds of an in-patient death decreased by 2.0% per quarter for both IDU-IE and non-IDU-IE cases following reporting (OR 0.98, 95% CI 0.97-0.99). CONCLUSIONS: Initiating public reporting was associated with a significant decrease in valve surgery for all IE cases, regardless of IDU status, and a reduction in-hospital mortality for patients with IE. Patients with IE may have less access to surgery as a consequence of public reporting. To understand how reduced valve surgery impacts overall mortality, future studies should examine the postdischarge mortality rate.
Authors: Imad M Tleyjeh; Ahmed Abdel-Latif; Hazim Rahbi; Christopher G Scott; Kent R Bailey; James M Steckelberg; Walter R Wilson; Larry M Baddour Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: Laura J Ball; Adeel Sherazi; Dora Laczko; Kaveri Gupta; Sharon Koivu; Matthew A Weir; Tina Mele; Rommel Tirona; John K McCormick; Michael Silverman Journal: Med Care Date: 2018-10 Impact factor: 2.983
Authors: Anuj Gupta; Robert W Yeh; Jacqueline E Tamis-Holland; Shalin H Patel; Robert A Guyton; Lloyd W Klein; Tanveer Rab; Ajay J Kirtane Journal: JACC Cardiovasc Interv Date: 2016-10-24 Impact factor: 11.195
Authors: Matthew O'Donnell; Honora Englander; Luke Strnad; Castigliano M Bhamidipati; Evan Shalen; Patricio A Riquelme Journal: J Gen Intern Med Date: 2022-01-11 Impact factor: 5.128
Authors: Simeon D Kimmel; Alexander Y Walley; Yijing Li; Benjamin P Linas; Sara Lodi; Dana Bernson; Roger D Weiss; Jeffrey H Samet; Marc R Larochelle Journal: JAMA Netw Open Date: 2020-10-01